A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
← catalyst calendarNCT07444476 · readout in 674 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
90estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-03 | estimated | When the study began enrolling |
| Primary completion | 2028-06-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-06-22 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Spinal Muscular Atrophy
Intervention
- Drug: Salanersen — also filed as BIIB115
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Total Score in Treatment-Naïve Cohort
measured At Month 12
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed